← Eichor
Condition: Universal Allogeneic Car T Cells Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Universal Allogeneic Car T Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
EARLY_Phase 1 · 1 location(s) · The Second Hospital of Anhui Medical University · NCT07530380Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07617285CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Phase 1 · 3 location(s) · Hangzhou Qihan Biotech Co., Ltd. · NCT07444307CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NA · 1 location(s) · Bioray Laboratories · NCT05988216Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in
EARLY_Phase 1 · 1 location(s) · Tianjin Huanhu Hospital · NCT06939166Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06920433Universal CAR-T Cell Therapy for MM
NA · 1 location(s) · Bioray Laboratories · NCT07248176Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 10 location(s) · Cellectis S.A. · NCT05607420CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07586267CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06733610
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.